Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Vogenx Q3 2026 Results: Net Loss of $4.91M, Loss Widens

Vogenx, Inc. is a clinical-stage biopharmaceutical company that has incurred significant losses since inception and expects to continue doing so for the foreseeable future. The company currently generates no revenue from product sales and requires substantial additional funding to advance its research and development programs, including its lead candidate mizagliflozin.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-4.9-0.3
EPS (diluted, $ a share)$-0.47$-0.05

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: VOGX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Vogenx, Inc.: key numbers

Share price
$14.38Close, Nov 16
Market cap
$214M
Shares outstanding
14.86MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Vogenx, Inc.

All →
6:48 AM ET 8-K
Financial Results

Vogenx Financial Results

Vogenx reported Q3 2026 financial results, its first as a public company following a $93.4 million IPO in August. The company ended the quarter with $82.1 million in cash and initiated its Phase 2b EMERGE study for mizagliflozin in post-bariatric hypoglycemia.

Term
Q3 2026

“Our third quarter performance marks a pivotal milestone for Vogenx following our successful public listing in August. The EMERGE study is now up and running and we have added critical headcount across the Company, positioning us to advance the development of mizagliflozin for both post-bariatric hypoglycemia (PBH) and gastroparesis.”

James Green, Chief Executive Officer of Vogenx
1:31 PM ET 8-K
Leadership Change

Vogenx Leadership Change

Richard Gorman has been appointed as Chief Commercial Officer of Vogenx, Inc., effective October 12, 2026. Concurrent with this appointment, Mr. Gorman resigned from his position as an independent member of the Board of Directors and its committees. The company will conduct a search for a new independent director to fill the board vacancy.

4:01 PM ET 8-K
Leadership Change

Vogenx Leadership Change

Vogenx, Inc. appointed Ken Toombs to its Board of Directors as an independent director and Chair of the Audit Committee, effective September 21, 2026. Mr. Toombs, the former CEO of PA Consulting, brings thirty years of experience in professional services and life sciences to the board as the company scales operations following its August 2026 IPO. Peter Pieraccini was also appointed to serve as Chair of the Compensation Committee.

Counterparty
Ken Toombs

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.